Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gelbard

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Journal of Urology|January 5, 2021
Editorial CommentMartin Gelbard
Urology|June 15, 2016
Editorial CommentMartin Gelbard
The Journal of Sexual Medicine|December 19, 2008
Myofibroblasts and mechanotransduction: do forces in the tunica albuginea contribute to Peyronie's disease?Martin Gelbard
The Journal of Sexual Medicine|November 1, 2007
RE: graft materials in Peyronie's disease surgery: a comprehensive review by Ates Kadioglu, MD, Oner Sanli, MD, et al. J Sex Med 2007;4:581-95Martin Gelbard
The Journal of Urology|April 17, 2012
Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie diseaseMartin Gelbard, Larry I Lipshultz, James Tursi, et al.
The Journal of Sexual Medicine|October 12, 2013
Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie's diseaseMartin Gelbard, Wayne J G Hellstrom, Chris G McMahon, et al.
The Journal of Urology|January 24, 2019
Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional AnalysisWayne J G Hellstrom, Hoang Minh Tue Nguyen, Laith Alzweri, et al.
Urology|August 11, 2020
Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute Phase Peyronie's Disease: A Multi-institutional AnalysisHoang Minh Tue Nguyen, Ayad Yousif, Amanda Chung, et al.
The Journal of Urology|February 5, 2013
Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studiesMartin Gelbard, Irwin Goldstein, Wayne J G Hellstrom, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Journal of Urology|January 5, 2021
Editorial CommentMartin Gelbard
Urology|June 15, 2016
Editorial CommentMartin Gelbard
The Journal of Sexual Medicine|December 19, 2008
Myofibroblasts and mechanotransduction: do forces in the tunica albuginea contribute to Peyronie's disease?Martin Gelbard
The Journal of Sexual Medicine|November 1, 2007
RE: graft materials in Peyronie's disease surgery: a comprehensive review by Ates Kadioglu, MD, Oner Sanli, MD, et al. J Sex Med 2007;4:581-95Martin Gelbard
The Journal of Urology|April 17, 2012
Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie diseaseMartin Gelbard, Larry I Lipshultz, James Tursi, et al.
The Journal of Sexual Medicine|October 12, 2013
Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie's diseaseMartin Gelbard, Wayne J G Hellstrom, Chris G McMahon, et al.
The Journal of Urology|January 24, 2019
Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie's Disease: Results of a Multi-Institutional AnalysisWayne J G Hellstrom, Hoang Minh Tue Nguyen, Laith Alzweri, et al.
Urology|August 11, 2020
Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute Phase Peyronie's Disease: A Multi-institutional AnalysisHoang Minh Tue Nguyen, Ayad Yousif, Amanda Chung, et al.
The Journal of Urology|February 5, 2013
Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studiesMartin Gelbard, Irwin Goldstein, Wayne J G Hellstrom, et al.
Pageof 1